JPWO2020180967A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020180967A5 JPWO2020180967A5 JP2021551927A JP2021551927A JPWO2020180967A5 JP WO2020180967 A5 JPWO2020180967 A5 JP WO2020180967A5 JP 2021551927 A JP2021551927 A JP 2021551927A JP 2021551927 A JP2021551927 A JP 2021551927A JP WO2020180967 A5 JPWO2020180967 A5 JP WO2020180967A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic protein
- hmw species
- mixture
- level
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (32)
a.(i)前記治療用タンパク質を含むサンプルと、(ii)血清又は枯渇血清の画分とを含む混合物をインキュベートすること、
及び
b.工程(a)後の1つ又は複数の時点で、前記混合物中に存在する前記治療用タンパク質のHMW種のレベルをアッセイすること
を含み、
(i)アッセイされる前記HMW種のサイズは、約0.1ミクロン未満のサイズであるか、
(ii)前記混合物中の前記治療用タンパク質のHMW種のレベルを、サイズ排除クロマトグラフィー(SEC)によりアッセイするか、又は
(iii)(i)及び(ii)の両方である、
インビトロ方法。 1. An in vitro method of assaying in vivo levels of high molecular weight (HMW) species of a therapeutic protein comprising:
a. incubating a mixture comprising (i) a sample comprising said therapeutic protein and (ii) serum or a fraction of depleted serum ;
and b. assaying the level of HMW species of said therapeutic protein present in said mixture at one or more time points after step (a) ;
( i) the size of said HMW species assayed is less than about 0.1 microns in size;
(ii) assaying the level of HMW species of said therapeutic protein in said mixture by size exclusion chromatography (SEC), or (iii) both (i) and (ii);
in vitro method.
a.前記治療用タンパク質を含むサンプルと、枯渇血清とを含む混合物をインキュベートする工程であって、前記枯渇血清は、予め選択された分子量範囲を有する分子が枯渇した画分であり、前記予め選択された分子量範囲は、約30kDa~約300kDaであるか、又はより高く、前記枯渇画分は、サイズに基づくろ過により得られた画分である、工程、
b.SECにより、工程(a)後の1つ又は複数の時点で、前記混合物中に存在する前記治療用タンパク質のHMW種のレベルをアッセイする工程、
c.工程(b)でアッセイされる際に前記混合物中に存在する前記HMW種のレベルと、工程(a)前に前記サンプル中に存在する前記HMW種のレベルとを比較する工程、
及び
d.前記治療用タンパク質の前記HMW種のインビボでの可逆性の割合を算出する工程
を含む方法。 A method for determining in vivo reversibility of HMW species of a therapeutic protein comprising:
a. incubating a mixture comprising a sample comprising said therapeutic protein and depleted serum, wherein said depleted serum is a fraction depleted in molecules having a preselected molecular weight range , said preselected the molecular weight range is about 30 kDa to about 300 kDa or higher , and said depleted fraction is a fraction obtained by size-based filtration;
b. assaying the level of HMW species of said therapeutic protein present in said mixture at one or more time points after step (a) by SEC;
c. comparing the level of said HMW species present in said mixture as assayed in step (b) to the level of said HMW species present in said sample prior to step (a);
and d. A method comprising calculating the percentage of in vivo reversibility of said HMW species of said therapeutic protein.
a.前記治療用タンパク質を含むサンプルと、枯渇血清とを含む混合物をインキュベートする工程であって、前記枯渇血清は、IgG枯渇血清画分である、工程、
b.捕捉分子による親和性クロマトグラフィーにより前記混合物の成分を分離して、前記治療用タンパク質及びそのHMW種を含む画分を得る工程、
c.SECにより、前記画分中に存在する前記治療用タンパク質のHMW種のレベルをアッセイする工程、
d.工程(c)でアッセイされる際に前記画分中に存在する前記HMW種のレベルと、工程(a)前に前記サンプル中に存在する前記HMW種のレベルとを比較する工程、
並びに
e.前記治療用タンパク質の前記HMW種のインビボでの可逆性の割合を算出する工程
を含む方法。 A method for determining in vivo reversibility of HMW species of a therapeutic protein comprising:
a. incubating a mixture comprising a sample comprising said therapeutic protein and depleted serum, wherein said depleted serum is an IgG depleted serum fraction;
b. separating the components of said mixture by affinity chromatography with a capture molecule to obtain a fraction containing said therapeutic protein and its HMW species;
c. assaying the level of HMW species of said therapeutic protein present in said fraction by SEC;
d. comparing the level of said HMW species present in said fraction as assayed in step (c) to the level of said HMW species present in said sample prior to step (a);
and e. A method comprising calculating the percentage of in vivo reversibility of said HMW species of said therapeutic protein.
a.前記治療用タンパク質を含むサンプルと、全血清とを含む混合物をインキュベートする工程であって、前記治療用タンパク質は、蛍光標識を含む、工程、
b.前記混合物を希釈する工程、
c.SECにより、工程(a)後の1つ又は複数の時点で、前記混合物中に存在する前記治療用タンパク質のHMW種のレベルをアッセイする工程、
d.工程(c)でアッセイされる際に前記混合物中に存在する前記HMW種のレベルと、工程(a)前に前記サンプル中に存在する前記HMW種のレベルとを比較する工程、
及び
e.前記治療用タンパク質の前記HMW種のインビボでの可逆性の割合を算出する工程
を含む方法。 A method for determining in vivo reversibility of HMW species of a therapeutic protein comprising:
a. incubating a mixture comprising a sample containing the therapeutic protein and whole serum, wherein the therapeutic protein comprises a fluorescent label;
b. diluting the mixture;
c. assaying the level of HMW species of said therapeutic protein present in said mixture at one or more time points after step (a) by SEC;
d. comparing the level of said HMW species present in said mixture as assayed in step (c) to the level of said HMW species present in said sample prior to step (a);
and e. A method comprising calculating the percentage of in vivo reversibility of said HMW species of said therapeutic protein.
a.前記治療用タンパク質を含むサンプルと、全血清とを含む混合物をインキュベートする工程、
b.捕捉分子による親和性クロマトグラフィーにより、前記混合物の成分を分離して、前記治療用タンパク質及びそのHMW種を含む画分を得る工程、
c.SECにより、前記画分中に存在する前記治療用タンパク質のHMW種のレベルをアッセイする工程、
d.工程(c)でアッセイされる際に前記画分中に存在する前記HMW種のレベルと、工程(a)前に前記サンプル中に存在する前記HMW種のレベルとを比較する工程、
並びに
e.前記治療用タンパク質の前記HMW種のインビボでの可逆性の割合を算出する工程
を含む方法。 A method for determining in vivo reversibility of HMW species of a therapeutic protein comprising:
a. incubating a mixture comprising a sample comprising said therapeutic protein and whole serum;
b. separating the components of said mixture by affinity chromatography with a capture molecule to obtain a fraction containing said therapeutic protein and its HMW species;
c. assaying the level of HMW species of said therapeutic protein present in said fraction by SEC;
d. comparing the level of said HMW species present in said fraction as assayed in step (c) to the level of said HMW species present in said sample prior to step (a);
and e. A method comprising calculating the percentage of in vivo reversibility of said HMW species of said therapeutic protein.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962813529P | 2019-03-04 | 2019-03-04 | |
US62/813,529 | 2019-03-04 | ||
US201962944758P | 2019-12-06 | 2019-12-06 | |
US62/944,758 | 2019-12-06 | ||
PCT/US2020/020956 WO2020180967A1 (en) | 2019-03-04 | 2020-03-04 | In vivo reversibility of high molecular weight species |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022522816A JP2022522816A (en) | 2022-04-20 |
JPWO2020180967A5 true JPWO2020180967A5 (en) | 2023-03-08 |
Family
ID=70277450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021551927A Pending JP2022522816A (en) | 2019-03-04 | 2020-03-04 | In vivo reversibility of high molecular weight species |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230035363A1 (en) |
EP (1) | EP3935396A1 (en) |
JP (1) | JP2022522816A (en) |
AU (1) | AU2020231509A1 (en) |
CA (1) | CA3130462A1 (en) |
MX (1) | MX2021010414A (en) |
WO (1) | WO2020180967A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA014802B1 (en) | 2001-08-23 | 2011-02-28 | Генмаб А/С | HUMAN ANTIBODIES SPECIFIC FOR INTERLEUKIN 15 (IL-15)\ (VARIANTS), A METHOD OF PRODUCING THEREOF, AN IMMUNOCONJUGATE BASED THEREON, A TRANSFECTOMA, A HYBRIDOMA, A TRANSGENIC ANIMAL, AN EXPRESSION VECTOR (VARIANTS) AND NUCLEIC ACID FOR PRODUCING THEREOF, A METHOD OF TREATMENT (VARIANTS) AND DIAGNOSING AN IL-15 MEDIATED DISEASE, A METHOD OF INHIBITING IL-15 INDUCED TNF-α, AND A METHOD OF INHIBITING INDUCED IL-15 CELL PROLIFERATION. |
US20060003384A1 (en) * | 2004-06-30 | 2006-01-05 | Wagner Carrie L | Detection of measurement of antibodies to antigenic proteins in biological tissues or samples |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
AU2008265128A1 (en) | 2007-06-20 | 2008-12-24 | Irm Llc | Methods and compositions for treating allergic diseases |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
MX343328B (en) * | 2009-10-26 | 2016-11-01 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies. |
-
2020
- 2020-03-04 CA CA3130462A patent/CA3130462A1/en active Pending
- 2020-03-04 JP JP2021551927A patent/JP2022522816A/en active Pending
- 2020-03-04 AU AU2020231509A patent/AU2020231509A1/en active Pending
- 2020-03-04 EP EP20718417.7A patent/EP3935396A1/en active Pending
- 2020-03-04 MX MX2021010414A patent/MX2021010414A/en unknown
- 2020-03-04 US US17/436,218 patent/US20230035363A1/en active Pending
- 2020-03-04 WO PCT/US2020/020956 patent/WO2020180967A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2293079B1 (en) | Use of precursors of enkephalins and/or their fragments in medical diagnostics | |
Granger et al. | Albumin depletion of human plasma also removes low abundance proteins including the cytokines | |
JP2521707B2 (en) | Inhibin isolated from follicular fluid | |
US9796777B2 (en) | Methods of treating malignant tumors | |
JP2006515561A (en) | Compositions and methods for assaying Apo-B48 and Apo-B100 | |
US20100112597A1 (en) | Methods for Quantifying Protein Leakage From Protein Based Affinity Chromatography Resins | |
FI95579B (en) | Immunological method and means for the selective determination of intact procollagen peptide (type III) and procollagen (type III) in body fluids | |
US20230279046A1 (en) | Size exclusion chromatography for characterizing host cell proteins | |
JP3245052B2 (en) | Antibodies to the amino-terminal propeptide of type I procollagen and assays using the same | |
Thevis et al. | Identification and characterization of peptides and proteins in doping control analysis | |
JPWO2020180967A5 (en) | ||
Kwok et al. | Administration study of recombinant human relaxin‐2 in horse for doping control purpose | |
Saginati et al. | A simple procedure for tenascin purification | |
AU682176B2 (en) | Method and compositions for recombinant osteogenic protein production | |
US5610021A (en) | Compositions and methods for identification and use of soluble complex forms of osteogenic proteins | |
WO2015129651A1 (en) | Modified monomeric igm | |
JP2888443B2 (en) | Methods for producing and measuring antibodies to human leukocyte interferon subspecies | |
JP2825583B2 (en) | Cellular protein immunoassay | |
Blokland et al. | Analysis for endogenous and recombinant porcine somatotropine in serum | |
JPH0616698A (en) | Separation and purification of polyclonal antibody | |
JP2013542453A (en) | Albumin binding protein / peptide complex as a biomarker for disease | |
JPH08505369A (en) | Purified TSH formulation, process for its preparation and its use in the production of TSH tracers for TSH receptor assay and in TSH receptor assay | |
EP2142933B1 (en) | Multi-immunoaffinity based antigen identification | |
JPS58137759A (en) | Immunologically active composite body | |
Idar et al. | Purification of IgY Anti-SARS-CoV-2-Chicken Nucleocapsid and Elimination of Its Low-temperature Storage-induced Aggregates |